Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell Lymphomas
Rizzitano S, Cavanè A, Piazzoni M, Vendramin A, Gimondi S, Biancon G, Malan S, Dodero A, Corradini P, Carniti C. Synergistic Anti-Tumor Efficacy of BET Inhibitors JQ1 and Otx-015 in Combination with Dasatinib in Preclinical Models of T-Cell Lymphomas. Blood 2016, 128: 3967. DOI: 10.1182/blood.v128.22.3967.3967.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaT-cell lymphomaT cell receptorChou-Talalay combination indexDose-dependent mannerCell cycle distributionFlow cytometryCell cycle arrestC-myc expressionPreclinical modelsTK inhibitorsCell linesLeukemia cell linesInhibitor dasatinibC-MycWestern blottingG1 populationGene expression profilingSynergistic anti-tumor effectBET inhibitorsLong-term remissionG0/G1 phase arrestStem cell transplantationSynergistic anti-tumor efficacyMitochondrial depolarization